Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Everpar Advisors LLC

Everpar Advisors LLC lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 760 shares of the medical research company’s stock after selling 137 shares during the quarter. Everpar Advisors LLC’s holdings in Thermo Fisher Scientific were worth $395,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Border to Coast Pensions Partnership Ltd grew its holdings in shares of Thermo Fisher Scientific by 12.3% in the fourth quarter. Border to Coast Pensions Partnership Ltd now owns 93,913 shares of the medical research company’s stock valued at $48,824,000 after purchasing an additional 10,305 shares in the last quarter. Woodstock Corp boosted its position in Thermo Fisher Scientific by 0.5% in the 4th quarter. Woodstock Corp now owns 15,763 shares of the medical research company’s stock valued at $8,200,000 after buying an additional 72 shares during the period. RDA Financial Network increased its position in shares of Thermo Fisher Scientific by 1.1% during the fourth quarter. RDA Financial Network now owns 4,303 shares of the medical research company’s stock worth $2,238,000 after acquiring an additional 47 shares during the period. Foresight Group Ltd Liability Partnership raised its stake in shares of Thermo Fisher Scientific by 43.9% in the fourth quarter. Foresight Group Ltd Liability Partnership now owns 1,750 shares of the medical research company’s stock valued at $908,000 after acquiring an additional 534 shares in the last quarter. Finally, KMG Fiduciary Partners LLC grew its stake in Thermo Fisher Scientific by 14.3% during the 4th quarter. KMG Fiduciary Partners LLC now owns 4,535 shares of the medical research company’s stock worth $2,359,000 after purchasing an additional 567 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $561.51 on Friday. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The business’s 50 day moving average is $529.69 and its two-hundred day moving average is $568.01. The stock has a market capitalization of $214.78 billion, a price-to-earnings ratio of 35.20, a PEG ratio of 3.59 and a beta of 0.76. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. Thermo Fisher Scientific’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter last year, the company earned $5.69 earnings per share. Research analysts expect that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Thermo Fisher Scientific declared that its board has authorized a share buyback program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were given a dividend of $0.39 per share. The ex-dividend date was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s payout ratio is 9.78%.

Insider Buying and Selling

In other news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the transaction, the senior vice president now owns 12,736 shares in the company, valued at $7,134,197.76. This trade represents a 13.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the sale, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,150 shares of company stock worth $25,954,465 in the last quarter. Company insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Morgan Stanley cut their target price on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating on the stock in a research note on Monday. Bank of America reduced their price objective on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Royal Bank of Canada cut their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Bernstein Bank increased their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a report on Tuesday, October 22nd. Finally, Scotiabank began coverage on Thermo Fisher Scientific in a report on Monday, December 23rd. They issued a “sector perform” rating and a $605.00 price target for the company. Four analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $648.95.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.